-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3915 CD10-CD14-hla-DR-CD45+SSC++ Neutrophils with G-MDSC-like Feature Relate to Progress and Poor Prognosis in Non-Hodgkins Lymphoma Patients

Program: Oral and Poster Abstracts
Session: 201. Granulocytes, Monocytes, and Macrophages: Poster III
Hematology Disease Topics & Pathways:
Research, Clinical Research, real-world evidence
Monday, December 11, 2023, 6:00 PM-8:00 PM

Ji Zhou1*, Yingwei Li2*, Xue Liang, PhD3* and Zhimin Zhai, MD4

1Department of Epidemiology and Health Statistics, Anhui Medical University, Hefei, China
2Hematologic Department of the Second Affiliated Hospital of Anhui Medical University, Hefei, China
3Hematologic Department, the Second Affiliated Hospital of Anhui Medical University, Hefei, China
4The Second Affiliated Hospital of Anhui Medical University, Hefei, China

Objectives: To explore CD10-CD14-CD45+HLA-DR⁻SSC++ neutrophils (CD10- neus) frequency in non-Hodgkins lymphoma (NHL) patients, and their immunologic characteristics and clinical significance. Methods: 90 NHL patients were involved, 47 age and gender-matched volunteers recruited as healthy controls (HC). The CD10- neus frequency in peripheral blood from the HC and NHL patients was detected. Then the CD10- and CD10+ neutrophils were isolated, and their morphologic characterization was compared. CD3+ T cells were also sorted for culture alone or co-culture with the autologous CD10+ or CD10- neutrophils for 48h, then the proliferation and viability of T cells were determined. The levels of Arg-1 and ROS in CD10+ or CD10- neutrophils were examined. Results: Little Few CD10- neus were detected in HC (1.94% ± 1.76), but the level was significantly elevated in newly diagnosed (NDP) and relapsed NHL patients (RLP), 37.90% ± 23.34 and 45.38% ± 20.89 respectively, there was a decrease in the remission patients (RMP, 26.62% ± 16.54). In NDP, CD10- neus at advanced stages was significantly higher than that at limited stages (50.16% ± 27.82 vs. 25.21±12.51, P = 0.017); similarly, the CD10- neus in patients with higher IPI score (3 to 5 points) more than that with lower IPI score ( 2) group (53.94% ± 29.09 vs. 30.33 ± 17.73, P = 0.0154). According to the median value of CD10- neus, we further divided the patients into CD10- neus high or low two subgroups, the remission rate after 2 - 4 times first-line treatments in NDP with high CD10- neuts significantly lower than that in patients with low CD10- neuts (12.5% vs 88.24%, P = 0.001); the relapse free survival (RFS) in RMP with high CD10- neus significantly shorter than that with low CD10- neus (11.5 vs. 33.5 months, P = 0.001); the overall survive (OS) in RLP with high CD10- neus also shorter than that with low CD10- neus (23 vs. 39.5 months, P = 0.001). The CD10- neus from NHL mainly consisted of immature neutrophils, strong inhibited T-cell proliferation and viability, Arg-1 and ROS in CD10- neutrophils neuts vastly increased comparing to that from HC. Conclusions: CD10- neus in NHL have the two main characteristics of MDSCs cells (immature and T cell inhibition), the increased may predict disease progression and poor prognosis.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH